Clear Scientific’s CEO and General Counsel joins GBH’s radio show The Curiosity Desk to discuss CS-1103 and its “Pac-Man” like capabilities.
Updated: Sep 3
Boston, MA | June 2026
Clear Scientific’s CEO, Shekar Shetty, and General Counsel, Winston Henderson, joined the June 9th Boston’s GBH radio show, The Curiosity Desk hosted by Edgar B. Herwick III. GBH’s newest show is live weekday afternoons from 1 to 2 p.m. EST and focuses on conversations, insights and profundities about the world we live in.
Tune in to listen to the Clear Scientific team discuss the development of the world’s first antidote to methamphetamine overdose.
About Clear Scientific:
Clear Scientific was co-founded in March 2019 by Professor George M. Whitesides of Harvard University with technology licensed from Massachusetts General Hospital and the University of Maryland.
Clear Scientific is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. The company is developing highly selective, small molecule sequestrants that bind, inactivate, and rapidly clear these excess compounds from the body. Clear Scientific receives funding from the National Institutes of Health (NIH) / National Institute on Drug Abuse (NIDA) and is working with their network of medical and academic professionals.
About CS-1103:
CS-1103 is a first-in-class injectable small molecule sequestrant that binds and inactivates target compounds, rapidly reversing their effects and accelerating their clearance into urine. Clear Scientific is initially targeting methamphetamine, fentanyl and cocaine overdose, representing close to 95% of drug fatalities in the US. The Company’s pipeline includes indications in substance use disorder, central nervous system (CNS) and metabolic diseases amongst others. CS-1103 is investigational and has not been approved by any health authority.
For more information, visit https://www.clearsci.com
Comments